Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome
- Conditions
- Turner SyndromeHypogonadismOvarianHormone Replacement TherapyEstrogen Replacement TherapyEstrogen Deficiency
- Registration Number
- NCT06570460
- Lead Sponsor
- Aarhus University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 50
<br><br>For participants with TS:<br><br> - Diagnosis of TS regardless of karyotype<br><br> - Age 18-50 years<br><br> - Already receiving estrogen treatment<br><br>For healthy controls:<br><br> - Female<br><br> - Age 18-50 years<br><br> - Previously healthy<br><br> - Not receiving any medication<br><br> - Not using any form of contraceptive pills<br><br> - No mental or psychiatric disorders<br><br>Exclusion criteria:<br><br> - Active systemic chronic diseases<br><br> - Known or suspected breast cancer<br><br> - Known or suspected estradiol-dependent tumors (endometrial cancer or similar)<br><br> - Untreated endometrial hyperplasia<br><br> - Current or previous venous thromboembolism<br><br> - Acute or previous liver disease where liver enzymes are still elevated by a factor 3<br> or more<br><br> - Known hypersensitivity to the medications used<br><br> - Pregnancy<br><br> - Menopause (for the control group only)
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood test values;Blood test values;Dual energy X-ray absorptiometry;Cardiovascular status;Cardiovascular status;Muscle quality (quadriceps femoris);Functional muscle tests;Isometric muscle tests;Maximal oxygen uptake test (VO2 max)
- Secondary Outcome Measures
Name Time Method Self-reported health-related quality of life and functioning (SF-36);Self-reported quality of life (WHOQoL-Bref);Subjective medication assesment